Comprehensive registry of esophageal cancer in Japan, 2014

Abstract

Background: The registration committee for esophageal cancer in the Japan Esophageal Society (JES) has collected the patients' characteristics, treatment, and outcomes annually.

Methods: We analyzed the data of patients who had visited the participating hospitals in 2014. We collected the data with a web-based data collection system using the National Clinical Database. We used the Japanese Classification of Esophageal Cancer 10th edition by JES and the TNM classification 7th edition by the Union of International Cancer Control (UICC) for cancer staging.

Results: A total of 9026 cases were registered from 344 institutions in Japan. Squamous cell carcinoma and adenocarcinoma accounted for 87.9% and 7.1%, respectively. The 5-year survival rates of patients treated using endoscopic resection, concurrent chemoradiotherapy, radiotherapy alone, and esophagectomy were 87.1%, 33.7%, 25.3%, and 59.3%, respectively. Esophagectomy was performed in 5204 cases. Concerning the approach used for esophagectomy, 48.1% of the cases were treated thoracoscopically. The operative mortality (within 30 days after surgery) was 0.75%, and the hospital mortality was 2.0%. The survival curves showed an excellent discriminatory ability both in the clinical and pathologic stages by the JES system. The survival of pStage IV was better than IIIC in the UICC system, because pStage IV included the patients with supraclavicular lymph-node metastasis (M1 LYM).

Conclusion: We hope that this report contributes to improving all aspects of diagnosing and treating esophageal cancer in Japan.

Keywords: Chemoradiotherapy; Chemotherapy; Endoscopic resection; Esophageal cancer; Esophagectomy; Radiotherapy.

Fig. 1

Survival of patients treated with EMR/ESD

Fig. 2

Survival of patients treated with EM/ESD according to the pathological depth of tumor invasion, pT (JES 10th)

Fig. 3

Survival of patients treated with EMR/ESD according to the lymphatic and venous invasion

Fig. 4

Survival of patients treated with chemotherapy and/or radiotherapy

Fig. 5

Survival of patients treated with definitive chemoradiotherapy according to the clinical stage (UICC TNM 7th)

Fig. 6

Survival of patients who underwent radiotherapy alone according to the clinical stage (UICC TNM 7th)

Fig. 7

Survival of patients who underwent esophagectomy

Fig. 8

Survival of patients who underwent esophagectomy according to the clinical stage (JES 10th)

Fig. 9

Survival of patients who underwent esophagectomy according to the clinical stage (UICC TNM 7th)

Fig. 10

Survival of patients who underwent esophagectomy according to the depth of tumor invasion, pT (JES 10th)

Fig. 11

Survival of patients who underwent esophagectomy according to lymph-node metastasis (JES 10th)

Fig. 12

Survival of patients who underwent esophagectomy according to lymph-node metastasis (UICC TNM 7th)

Fig. 13

Survival of patients who underwent esophagectomy according to the pathological stage (JES 10th)

Fig. 14

Survival of patients who underwent esophagectomy according to the pathological stage (UICC TNM 7th)

Fig. 15

Survival of patients